NZ597538A - Regioselective preparation of 2 -amino-5-trifluoromethylpyrimidine derivatives - Google Patents

Regioselective preparation of 2 -amino-5-trifluoromethylpyrimidine derivatives

Info

Publication number
NZ597538A
NZ597538A NZ597538A NZ59753810A NZ597538A NZ 597538 A NZ597538 A NZ 597538A NZ 597538 A NZ597538 A NZ 597538A NZ 59753810 A NZ59753810 A NZ 59753810A NZ 597538 A NZ597538 A NZ 597538A
Authority
NZ
New Zealand
Prior art keywords
group
formula
amino
optionally substituted
suitable substituents
Prior art date
Application number
NZ597538A
Other languages
English (en)
Inventor
Guenter Linz
Gerd Kraemer
Sabrina Kusserow
Juergen Schnaubelt
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42712695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ597538(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NZ597538A publication Critical patent/NZ597538A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ597538A 2009-08-14 2010-08-13 Regioselective preparation of 2 -amino-5-trifluoromethylpyrimidine derivatives NZ597538A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09167934 2009-08-14
PCT/EP2010/061840 WO2011018518A1 (en) 2009-08-14 2010-08-13 Regioselective preparation of 2 -amino-5-trifluoromethylpyrimidine derivatives

Publications (1)

Publication Number Publication Date
NZ597538A true NZ597538A (en) 2014-05-30

Family

ID=42712695

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ597538A NZ597538A (en) 2009-08-14 2010-08-13 Regioselective preparation of 2 -amino-5-trifluoromethylpyrimidine derivatives

Country Status (17)

Country Link
US (1) US8933227B2 (enExample)
EP (1) EP2464634B1 (enExample)
JP (1) JP5539519B2 (enExample)
KR (1) KR20120046248A (enExample)
CN (1) CN102471287A (enExample)
AR (1) AR077925A1 (enExample)
AU (1) AU2010283713A1 (enExample)
BR (1) BR112012002971A2 (enExample)
CA (1) CA2767965A1 (enExample)
CL (1) CL2012000278A1 (enExample)
EA (1) EA201200282A1 (enExample)
IL (1) IL217112A0 (enExample)
IN (1) IN2012DN01342A (enExample)
MX (1) MX2012001469A (enExample)
NZ (1) NZ597538A (enExample)
TW (1) TW201124385A (enExample)
WO (1) WO2011018518A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2718858A1 (en) * 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Selective synthesis of substituted pyrimidines
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
CN102887860B (zh) * 2012-09-29 2015-07-01 上海泰坦科技有限公司 4-氯-6-三氟甲基嘧啶类化合物的制备方法
JP6391985B2 (ja) * 2014-05-16 2018-09-19 東ソー・ファインケム株式会社 2−置換−4−(2,2,2−トリフルオロエトキシ)−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法
JP6391988B2 (ja) * 2014-05-21 2018-09-19 東ソー・ファインケム株式会社 5−(トリフルオロメチル)ピリミジン誘導体の製造方法及び新規5−(トリフルオロメチル)ピリミジン誘導体
JP6262079B2 (ja) * 2014-06-02 2018-01-17 東ソー・ファインケム株式会社 4−(2,2,2−トリフルオロエトキシ)−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法
JP6431294B2 (ja) * 2014-06-16 2018-11-28 東ソー・ファインケム株式会社 5−(トリフルオロメチル)ピリミジン誘導体及びその製造法
JP6479486B2 (ja) * 2015-01-16 2019-03-06 東ソー・ファインケム株式会社 4−アルコキシ−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262A (ja) 1986-03-05 1987-01-06 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物の製造方法
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
EP1438053B1 (de) 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
DE10161763A1 (de) 2001-12-15 2003-07-17 Bayer Cropsience Ltd Neues herbizides Verfahren
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003231231A1 (en) 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
EA200500721A1 (ru) 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
CA2529611C (en) 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005023780A1 (en) 2003-09-05 2005-03-17 Pfizer Products Inc. Selective synthesis of cf3-substituted pyrimidines
JP2007505858A (ja) 2003-09-18 2007-03-15 ノバルティス アクチエンゲゼルシャフト 増殖性障害の処置に有用な2,4−ジ(フェニルアミノ)ピリミジン
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005111023A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
CA2571937A1 (en) 2004-07-08 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of pkc-theta
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
AU2005322855B2 (en) 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
EP1705177A1 (en) 2005-03-23 2006-09-27 Schering Aktiengesellschaft N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents
CN101218229A (zh) 2005-05-05 2008-07-09 阿斯利康(瑞典)有限公司 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
DK1945631T3 (da) 2005-10-28 2012-10-22 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
US8722884B2 (en) 2005-12-01 2014-05-13 Verastem, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2007072158A2 (en) 2005-12-21 2007-06-28 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
TW200804364A (en) 2006-02-22 2008-01-16 Boehringer Ingelheim Int New compounds
WO2007115999A1 (en) 2006-04-10 2007-10-18 Boehringer Ingelheim International Gmbh 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
AR060890A1 (es) 2006-05-15 2008-07-23 Boehringer Ingelheim Int Compuestos derivados de pirimidina y composicion farmaceutica en base a ellos
CA2652397A1 (en) 2006-05-18 2007-11-29 Boehringer Ingelheim International Gmbh Method of preparing chiral cyclic .beta.-aminocarboxamides
DE102006027156A1 (de) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
CA2654670A1 (en) 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh New compounds
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
WO2008040951A1 (en) 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
WO2008045978A1 (en) 2006-10-10 2008-04-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
WO2008046216A1 (en) 2006-10-18 2008-04-24 Methylgene, Inc. Kinase inhibitors and uses thereof
CA2666762C (en) 2006-10-19 2014-12-30 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
EP2222647B1 (en) 2006-10-23 2015-08-05 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
AU2007332654B2 (en) 2006-12-13 2013-06-20 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
EP2099771A1 (en) 2006-12-19 2009-09-16 Genentech, Inc. Pyrimidine kinase inhibitors
EP1939185A1 (de) 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs
US8247421B2 (en) 2006-12-21 2012-08-21 Vertex Pharmaceuticals Incorporated 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
EP2109605B1 (en) 2006-12-22 2013-02-20 Boehringer Ingelheim International GmbH 2- [(phenylamino) -pyrimidin-4ylamin0] -cyclopentane carboxamide derivatives and related compounds as inhibitors of kinases of the cell cycle for the treatment of cancer
CL2008000197A1 (es) 2007-01-26 2008-08-01 Smithkline Beecham Corp Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
US7947698B2 (en) 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
DK2146779T3 (en) 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
AU2008275918B2 (en) 2007-07-17 2014-01-30 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as PKC inhibitors
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
MX2010002336A (es) 2007-08-28 2010-03-25 Irm Llc Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa.
WO2009063240A1 (en) 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
WO2009071535A1 (en) 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
ES2389752T3 (es) 2007-12-14 2012-10-31 Ardea Biosciences, Inc. Inhibidores de la transcriptasa inversa
CA2718858A1 (en) 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Selective synthesis of substituted pyrimidines
UY31714A (es) 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
CA2729546A1 (en) 2008-06-25 2009-12-30 Irm Llc Compounds and compositions as kinase inhibitors
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
SG10201510696RA (en) 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
EP2179992A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
EP2179991A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
UY32240A (es) 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives

Also Published As

Publication number Publication date
EP2464634B1 (en) 2016-11-30
IN2012DN01342A (enExample) 2015-06-05
US8933227B2 (en) 2015-01-13
CA2767965A1 (en) 2011-02-17
CL2012000278A1 (es) 2012-10-12
AR077925A1 (es) 2011-10-05
EP2464634A1 (en) 2012-06-20
US20110190499A1 (en) 2011-08-04
BR112012002971A2 (pt) 2015-10-13
EA201200282A1 (ru) 2012-09-28
TW201124385A (en) 2011-07-16
KR20120046248A (ko) 2012-05-09
JP2013501759A (ja) 2013-01-17
AU2010283713A1 (en) 2012-02-02
CN102471287A (zh) 2012-05-23
WO2011018518A1 (en) 2011-02-17
JP5539519B2 (ja) 2014-07-02
MX2012001469A (es) 2012-02-22
IL217112A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
NZ597538A (en) Regioselective preparation of 2 -amino-5-trifluoromethylpyrimidine derivatives
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
AU2015221439B2 (en) Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
NZ600119A (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
UA105786C2 (uk) Адитивні солі амінів, що містять гідроксильні і/або карбоксильні групи, з похідними амінонікотинової кислоти як інгібітори dhodh
NZ599549A (en) Methods of synthesis and purification of heteroaryl compounds
EA201201033A1 (ru) Циклический амин и акарицид
MX370455B (es) Ácidos picolínicos y piridimin-4-carboxílicos sustituidos, procedimiento para su preparación y su uso como herbicidas y reguladores del crecimiento de plantas.
NZ599342A (en) Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
SG195118A1 (en) Process for the production of estetrol intermediates
MX2009005440A (es) Procedimiento para la produccion de derivados de fenilalanina que tienen estructuras de base de quinazolinodiona e intermediarios para la produccion.
EA201170098A1 (ru) Замещенные производные алкилпиримидин-4-она
MX352470B (es) Disales de acido malonico y metodo para preparar dihaluros de malonilo.
WO2009154754A3 (en) Synthesis of deuterated morpholine derivatives
MX2013000295A (es) Procedimiento de preparacion de un inhibidor especifico de la trombina.
TW200630363A (en) Process for preparing trisubstituted pyrimidine compounds
SG179206A1 (en) Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
IN2012DN01104A (enExample)
IN2015DN02424A (enExample)
IL200323A0 (en) Synthesis of glyt-1 inhibitors
MX2012007870A (es) Derivados de acido carboxilico que comprende un anillo de oxazolopirimidina 2, 5, 7-sustituido.
MX2010009876A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente.
NO20081859L (no) Fremgangsmate for fremstillingen av sartanderivater og mellomprodukter som er nyttige i slike fremgangsmater
MX2012007833A (es) Derivados de acido carboxilico heterociclicos que contienen un anillo de oxazolopirimidina 2, 5, 7 - sustituido.
WO2009131493A3 (ru) Производные 5-гидpoкcи-4-aминoмeтил-l-циклoгeкcил (или циклoгeптил)--3-aлкoкcикapбoнилиндoлoв, их фармацевтически приемлемые соли, обладающие противовирусной активностью, и способ их получения

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed